Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies by Schoffski, P. et al.
ORIGINAL ARTICLE
Spisulosine (ES-285) given as a weekly three-hour intravenous
infusion: results of a phase I dose-escalating study in patients
with advanced solid malignancies
P. Scho¨ffski • H. Dumez • R. Ruijter • B. Miguel-Lillo •
A. Soto-Matos • V. Alfaro • G. Giaccone
Received: 23 December 2010 / Accepted: 4 March 2011 / Published online: 5 April 2011
 Springer-Verlag 2011
Abstract
Purpose Spisulosine is a marine compound that showed
antitumor activity in preclinical studies. We report results
of a phase I trial performed in patients with advanced solid
tumors with the marine compound, with the aim to deter-
mine the maximum tolerated dose (MTD) of a weekly 3-h
intravenous (iv.) infusion, and to evaluate the safety, effi-
cacy, and pharmacokinetics (PK) of the compound.
Patients and methods Two centers contributed 25
patients to the trial, and 7 dose levels were explored.
Results In dose levels ranging from 4 to 128 mg/m2/day,
no dose-limiting toxicities (DLT) were observed. One
patient had DLT at 200 mg/m2, a reversible grade 3 ALT
increase. The MTD was not reached due to early termi-
nation of the Spisulosine trial program but is considered to
be likely in the range of 200 mg/m2 for this schedule.
Drug-related adverse reactions included mild to moderate
nausea, pyrexia, injection site reactions, and vomiting. One
case of grade 4 peripheral motor and sensory neuropathy
associated with general weakness and pain was observed
during treatment cycle 4 and possibly contributed to the
death of the patient. Grade 3 laboratory abnormalities
included anemia and lymphopenia and increases in liver
enzymes (alkaline phosphatase, transaminases, and biliru-
bin). Objective responses were not observed, and only four
patients had short-lasting stable disease (\3 months). The
PK data indicated a wide distribution, a long residence
time, and dose proportionality of the agent.
Conclusions Hepato- and neuro-toxicity are schedule
independent dose-limiting adverse events for this marine
compound, as illustrated by this and other early clinical
trials.
Keywords ES-285  Spisulosine  Phase I  Marine
compounds  Pharmacokinetics  Hepatotoxicity 
Neurotoxicity
Introduction
Spisulosine (ES-285, PM95118, IL0111) is the analog of a
phospholipid sphingosine, which was isolated from the
marine mollusk Spisula polynyma [1] (Fig. 1, 2). Preclin-
ical studies indicated strong antineoplastic potential against
a variety of malignancies, ranging from hematological
malignancies to solid tumors [1–3]. The mechanism of
action of Spisulosine, which induces programmed cell
death in vitro, is still speculative. GTP binding protein
regulating actin stress fibers has been proposed as a
potential molecular target, as tumor cells exposed to the
agent show suggestive phenotypic changes and expression
profiling data indicated modulation of genes related to the
actin cytoskeleton [4]. Spisulosine seems also to be capable
of activating caspases 3 and 12, the poly ADP-ribose
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polymerase pathway, and p53 phosphorylation [5]. Four
different administration schemes of single-agent Spisolu-
sine have been assessed in separate clinical phase I studies
[6–9]. The current trial evaluated a 3-h infusion given i.v.
every week in 3-week intervals, with the objective to
identify the MTD, to establish the safety profile of this
schedule, to assess preliminary signs of antitumor activity,
and to assess the PK profile of this novel compound.
Patients and methods
Patient selection
Patients had a histologically confirmed solid tumor and had
exhausted standard treatment options, were 18–70 years
old, had no acute adverse effects from prior treatments, a
life expectancy C12 weeks, measurable or non-measurable
disease according to RECIST [10], Eastern Cooperative
Oncology Group performance status of 0–2 and good organ
function (creatinine \1.5 mg/dl or calculated creatinine
clearance [60 ml/min; alanine aminotransferase [ALT]
and aspartate aminotransferase [AST] B2.5 9 upper limit
of normal [ULN]; bilirubin B1.5 9 ULN); absolute neu-
trophil count [ANC] C1.5 9 109/l, platelets C100 9 109/l);
left ventricular ejection fraction C50%).
In case of clinically relevant preexisting comorbidity,
increased cardiac risk, brain metastasis or if they had
received chemotherapy, radiotherapy or biological therapy
within 4 weeks or immunosuppressors within 3 weeks
previous to enrollment, patients were excluded from trial
participation. Pregnant or lactating women were not
entered. All patients provided written informed consent,
and ethics committee approval was obtained in both
involved clinical sites.
Study design
Patients were recruited from centers in Belgium (Univer-
sity Hospital Gasthuisberg, Leuven) and in the Netherlands
(Free University Hospital, Amsterdam). Spisulosine, sup-
plied as 50 mg of lyophilized powder by PharmaMar S.A.,
Spain, was reconstituted in 5 ml of water and made up to
250 ml with 5% dextrose and given weekly as a 3-h i.v.
infusion for at least one three-week cycle [11, 12]. Dose
escalation was performed in subsequent cohorts of 3 to a
maximum of 6 patients. The starting dose was 4 mg/m2/
day (total dose of 12 mg/m2 per cycle), corresponding to
30% of the MTD in mice. Interpatient dose escalation up to
200 mg/m2/day was considered by protocol. The dose was
doubled per cohort until dose-limiting toxicity (DLT) was
observed. The DLT window was the first 6 weeks of
treatment (first two three-week cycles), and DLT was
defined as a treatment delay[2 weeks, ANC\0.5 9 109/l
for [5 days or \1.0 9 109/l with fever, platelets
\25 9 109/l, a relative decrease in LVEF C20% compared
to the pre-study assessment, or any other grade 3/4 non-
hematological adverse event except for non-adequately
treated nausea/vomiting. In the absence of DLT during the
first two treatment cycles, three patients were treated per
dose level. A 3-week safety interval was mandated by
protocol before the second and third patient of a cohort
could start treatment. If DLT occurred, up to three addi-
tional patients were treated. If two or more experienced
DLT, this dose level was considered the MTD for this
schedule. The recommended dose for further clinical
studies was defined as the highest dose level where DLT
was observed in less than two out of six trial participants.
Clinical assessments
Routine medical examinations were performed at the start
of every cycle and before administering the weekly drug
infusion. Electrocardiogram, blood counts, and serum
chemistry including cardiac enzymes were performed
weekly. Tumor response was evaluated every 6 weeks
according to RECIST [10], adverse events were scored
continuously following the National Cancer Center Com-
mon Toxicity Criteria (NCI-CTC) v. 2.0.
Fig. 1 Chemical structure of Spisulosine (molecular formula
C18H39NO)
Fig. 2 Spisula polynyma (Alaska)
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Pharmacokinetics
Heparinized blood samples (5 ml) were collected accord-
ing to protocol and analyzed centrally with a validated
high-performance liquid chromatography system coupled
with electrospray ionization tandem mass spectrometry
(1.0 ng/ml limit of quantification) [13].
WinNonlin software (version 5.0.1) with standard non-
compartmental methods was used to calculate the area
under the plasma concentration curve from time 0 to the
last quantifiable concentration [AUClast], peak plasma
concentration (Cmax), total body clearance (CL), terminal
half-life (t1/2), and volume of distribution (Vz), and the
statistical analysis was done with SAS version 8.2 (SAS
Institute, Cary, NC).
Results
Patient characteristics
Twenty-five patients were treated between May 2003 and
November 2005, with 23/25 being evaluable for the safety
and efficacy endpoints of the trial. Patient characteristics
are shown in Table 1. Malignant melanoma (n = 5
patients), colorectal cancer (n = 4), prostate cancer
(n = 2), and chondrosarcoma (n = 2) were the most
common entities. All patients had metastatic disease at
study entry, and all but one had received prior chemo-
therapy (96%), with a median of three lines per patient
(range, 1–10).
Dose escalation and DLTs
All 7 dose levels planned according to protocol were
visited, and doses were escalated until 200 mg/m2/day
(Table 2). Sixty-one cycles were administered with a
median of 2 cycles per patient (range, 1–5). Treatment was
discontinued due to disease progression (n = 22 patients),
adverse events (n = 2), or withdrawal of consent (n = 1).
The median cumulative administered dose was 160 mg/m2
(range, 8–2,400 mg/m2), with a median relative dose
intensity of 83% (range, 33–102%).
One patient experienced a DLT, a reversible grade 3
increase in serum ALT in the first cycle at the highest dose
level of 200 mg/m2/day (Table 2). One patient experienced
grade 4 sensory and motor neuropathy during cycle 4,
which possibly contributed to the patient’s subsequent
death. An autopsy was not performed. MTD was not for-
mally reached due to early study termination, following a
consensual agreement between the sponsor and investiga-
tors involved in the Phase I program of Spisulosine, based
on fatal neurotoxicity experienced by a patient in a parallel
trial, the observation of grade 4 neuropathy during con-
secutive treatment cycles of patients in our trial and limited
evidence of antitumor activity in this and other studies. The
MTD is likely in the range of 200 mg/m2/day for the
weekly 3-h schedule, with one DLT observed in cycle 1 in
this prematurely closed study.
Overall tolerability
The most frequent adverse events were nausea, pyrexia,
injection site reactions/phlebitis, and vomiting (20, 20, 20,
and 16% of patients, respectively; Table 3). All drug-
related AEs were mild (grade 1 or 2), with the exception of
a patient who developed grade 4 peripheral motor and
grade 4 sensory neuropathy during cycle 4 of treatment.
The most frequent hematological events were anemia (all
patients, 20% with grade 3) and lymphopenia (72% of
patients, 20% with grade 3). The most common biochemical
abnormalities were increases in serum alkaline phosphatase
and transaminase levels. The incidence of other biochemical
abnormalities was low. Three patients had grade 3 AST
increases, and 2 patients had grade 3 ALT increases, one
of these events qualifying as the only DLT observed in this
trial.
Drug-related serious adverse events included one patient
with pyrexia and one patient with neuropathy. The first
patient was a 61-year-old male with metastatic colorectal
cancer who developed fever up to 40 degrees Celsius after
the first administration of Spisulosine 32 mg/m2; he
recovered without sequelae and received further infusions
without similar complications. The second patient was a
69-year-old male with metastatic melanoma who received
Table 1 Patient characteristics
Characteristics N
No. of patients 25
Male/female 17/8
Median age in years (range) 54 (21–74)
ECOG performance status 0/1/2 9/14/2
Primary cancer
Melanoma 5
Colorectal 4
Chondrosarcoma 2
Prostate 2
Other (n = 1/tumor type) 12
Metastatic 25
Median N of involved sites (range) 3 (1–6)
Prior therapy
Chemotherapy 24
Median N of lines (range) 3 (1–10)
ECOG Eastern cooperative oncology group
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8 infusions of the agent at a dose of 128 mg/m2. He
developed grade 1 numbness of the face, hands, and feet
prior to the eighth weekly infusion; his symptoms wors-
ened rapidly with the occurrence of neuropathy, pain, and
general weakness to grade 4, which ultimately also con-
tributed to his subsequent death according to the investi-
gator’s assessment. The patient had no other known risk
factors for neuropathy, had no relevant comorbidities and
did not receive any other drug associated with potential
neurotoxicity. The sensor and motor neuropathy of this
patient did not respond to treatment with vitamin B12 or
pregabalin. At time of onset of the neuropathy, he had no
evidence of disease progression, but the best overall
response to spisulosine was progressive disease.
Table 2 Dose escalation and
dose-limiting toxicity for
Spisulosine
Total number of cycles = 61
DLT Dose-limiting toxicity
Dose level
(mg/m2/day)
No. of
patients
No. of cycles,
median (range)
Days on study,
median (range)
No. of patients
with DLT
4 3 2 (2–2) 27 (26–42) 0
8 5 2 (1–3) 27 (7–49) 0
16 3 2 (2–4) 28 (28–70) 0
32 3 2 (2–2) 28 (28–28) 0
64 3 4 (2–5) 70 (28–92) 0
128 3 3 (2–4) 49 (29–77) 0
200 5 2 (1–5) 28 (7–91) 1
Total 25 61 28 (7–92) 1
Table 3 Grade 3 treatment-emergent toxicities per patient
Dose level
(mg/m2)
No. of
patients
treated
No. of patients
Anemia Lymphopenia AST
increase
ALT increase AP
increase
Bilirubin
increase
4–32 14 3 (21%) 3 (21%) – – 3 (21%) 2 (14%)
64 3 1 (33%) 1 (33%) 1 (33%) 1 (33%) 1 (33%) –
128 3 – – – – – –
200 5 1 (20%) 1 (20%) 2 (40%) 1 (20%) – 1 (20%)
Total 25 5 (20%) 5 (20%) 3 (12%) 2 (8%) 3 (12%) 3 (12%)
In addition to these grade 3 laboratory events, a case of grade 4 peripheral motor neuropathy and grade 4 peripheral sensory neuropathy was
observed in one patient in the 128 mg/m2 dose cohort
Grade 1/2 clinical adverse events included injection site reactions (20% of all patients), pyrexia (20%), nausea (20%), vomiting (16%), asthenia
(12%), myalgia (8%), limb pain (8%), back pain (4%), dysgeusia (4%), headache (4%), paresthesia (4%), and hot flushes (4%)
Table 4 Summary of pharmacokinetic parameters on day 1
Dose
(mg/m2/day)
No. of
evaluable patients
Cmax
(ng/ml)
AUClast
(h ng/ml)
AUC
(h ng/ml)
CL
(L/h)
Vz
(L)
t1/2
(h)
4 2 9.3 (17.4) 24.3 (5.2) 31.7 (33.2) 258.4 (34.6) 1,521.5 (114.9) 5.2 (124.7)
8 5 68.0 (95.7) 204.5 (59.8) 302.1 (70.7) 92.8 (93.4) 2,554.3 (93.1) 41.2 (94.4)
16 3 41.1 (8.4) 170.0 (28.4) 272.5 (38.1) 113.0 (40.6) 7,152.3 (14.6) 50.8 (51.3)
32 3 58.9 (32.3) 167.4 (31.3) 171.4 (30.9) 400.0 (43.1) 1,205.6 (47.1) 2.1 (4.0)
64 3 168.0 (1.6) 522.6 (25.2) 575.5 (30.3) 224.5 (33.9) 7,576.5 (99.7) 32.2 (123.8)
128 3 379.7 (18.1) 1,292.8 (11.5) 1,416.2 (13.5) 169.2 (22.4) 11,299.0 (95.2) 48.7 (103.3)
200 4 658.0 (12.5) 2,926.2 (54.1) 3,287.6 (57.9) 142.4 (40.9) 13,462.5 (78.6) 60.9 (58.5)
Values are mean (coefficient of variation, %)
AUC Area under the plasma concentration–time curve, CI confidence interval, CL clearance, Cmax maximum plasma concentration, t1/2 terminal
phase half-life, Vz volume of distribution
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Fig. 3 a Representative
concentration-time plot for
Spisulosine administered on day
1 as a 3-h intravenous infusion
(200 mg/m2). b (I) Peak plasma
concentration (Cmax) versus
total dose; (II) Area under the
curve versus total dose
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Antitumor activity
No objective responses were seen among twenty-three
evaluable patients. Four patients (two patients with mela-
noma, and one each with ovarian cancer and chondrosar-
coma) showed stable disease, lasting for less than
3 months.
Pharmacokinetics
Twenty-three patients were evaluated for PK (Table 4),
which was characterized by a wide distribution (dose-
dependent median volume of distribution [VSS] ranging
between 1,638 and 6,505 liters) and a long body residence
with a median t1/2 of 61 h (range, 28–94 h). PK indicated
dose linearity, but the sample size was too limited to draw
definitive conclusions (Table 4; Fig. 3a, b).
Discussion
Spisulosine, a compound of marine origin, which has
antitumor activity in preclinical models [1, 6], was studied
as a weekly 3-h i.v. infusion in doses ranging from 4 to
200 mg/m2. This schedule was generally well tolerated, as
illustrated by the low incidence of drug-related grade 3/4 or
serious adverse events. Of note, three patients had grade 3
AST increases, and 2 patients had grade 3 ALT increases,
one of these adverse drug reactions qualifying as the only
DLT observed in this trial. These safety findings are con-
sistent with preclinical investigations and other early
clinical studies [6–9], with reversible transaminase
increases reported at the highest doses in concurrent phase
I clinical trials with Spisulosine using 3 and 24-h i.v.
infusions every 3 weeks.
As was the case with the 24-h every 3-week schedule,
infusion site reactions were relatively common in this study
but did not require dose or schedule modifications. Pre-
clinical toxicity studies suggested that cardiotoxicity could
be dose limiting for this compound, but this was not con-
firmed in our clinical series. Overall, the toxicity profile
was consistent between the different administration
schedules, with notable toxicities being mainly hepatic and
neurological.
Drug-related neurotoxicity has been a common feature
in a number of clinical studies with various compounds of
natural origin and especially with some marine agents [14,
15]. The neurological events observed in the Phase I pro-
gram of Spisulosine include cases of sensory or motor
neuropathy, neuropathic pain, dizziness, apraxia, aphasia,
headache, somnolence, tremor, and decreased level of
consciousness. One patient treated with Spisulosine
200 mg/m2 as a 24-h i.v. infusion developed grade 3 drug-
related central neurotoxicity, which led to the patient’s
death 6 days after the first administration of the experi-
mental agent [6]. The neurotoxic potential of the drug was
confirmed in our study. Of note, the neurotoxicity of
Spisulosine was described as being more acceptable in
another Phase I trial [7]. The pathophysiology of the
neurotoxicity of the agent is currently unknown.
The PK profile of Spisulosine in this schedule showed a
wide distribution and a long terminal half life, with no
evidence of clinically relevant accumulation and a bi-
exponential elimination phase. There was an apparent
linear relationship between Spisulosine dose and exposure
according to Cmax and AUC.
Recruitment of patients to Spisulosine clinical trials was
discontinued during exploration of the last dose level in
this study, due to an unfavorable risk/benefit balance, and
due to the absence of clinically meaningful antitumor
efficacy in the whole clinical program. At that time, only
short-lasting stable disease had been reported as efficacy
signal from these trials. The seriousness of the neurological
toxicity experienced by one patient [6] supported this
decision.
In our trial, further patient recruitment and the expan-
sion of the recommended dose cohort were not imple-
mented for ethical reasons. The MTD for this schedule can
be estimated to be 200 mg/m2/day or higher. There was no
convincing preliminary evidence of clinical antitumor
efficacy.
In conclusion, hepato- and neurotoxicity are likely dose
limiting for Spisulosine in the weekly 3-h schedule, which
is in line with the results of other phase I trials and led to
discontinuation of the clinical development of this marine
compound.
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